https://scholars.lib.ntu.edu.tw/handle/123456789/627039
標題: | Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer | 作者: | Blackhall, Fiona Ross Camidge, D Shaw, Alice T Soria, Jean-Charles Solomon, Benjamin J Mok, Tony Hirsh, Vera Jänne, Pasi A Shi, Yuankai PAN-CHYR YANG Pas, Tommaso De Hida, Toyoaki Carpeño, Javier De Castro Lanzalone, Silvana Polli, Anna Iyer, Shrividya Reisman, Arlene Wilner, Keith D Kim, Dong-Wan |
關鍵字: | Alk; clinical trial; crizotinib; profile 1005 | 公開日期: | 2017 | 出版社: | ELSEVIER | 卷: | 2 | 期: | 3 | 來源出版物: | ESMO open | 摘要: | Crizotinib is a potent, orally administered tyrosine kinase inhibitor approved for the treatment of anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer (NSCLC). We report final results from PROFILE 1005, the largest clinical trial to date for an ALK inhibitor in ALK-positive NSCLC. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/627039 | ISSN: | 2059-7029 | DOI: | 10.1136/esmoopen-2017-000219 |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。